CNL
MCID: CHR286
MIFTS: 42

Chronic Neutrophilic Leukemia (CNL)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Chronic Neutrophilic Leukemia

MalaCards integrated aliases for Chronic Neutrophilic Leukemia:

Name: Chronic Neutrophilic Leukemia 12 52 58 15 17 71
Leukemia Neutrophilic Chronic 54
Cnl 52

Characteristics:

Orphanet epidemiological data:

58
chronic neutrophilic leukemia
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080187
NCIt 49 C3179
MESH via Orphanet 44 D015467
ICD10 via Orphanet 33 D47.1
UMLS via Orphanet 72 C0023481
Orphanet 58 ORPHA86829
UMLS 71 C0023481

Summaries for Chronic Neutrophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene.

MalaCards based summary : Chronic Neutrophilic Leukemia, also known as leukemia neutrophilic chronic, is related to polycythemia and splenomegaly. An important gene associated with Chronic Neutrophilic Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Ketamine and Dextromethorphan have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent... more...

Related Diseases for Chronic Neutrophilic Leukemia

Diseases related to Chronic Neutrophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 124, show less)
# Related Disease Score Top Affiliating Genes
1 polycythemia 30.3 TET2 JAK2 CALR
2 splenomegaly 30.2 SETBP1 JAK2 IFNA2 IFNA1
3 refractory anemia 29.9 TET2 CSF3 ASXL1
4 severe congenital neutropenia 29.9 JAK2 CSF3R CSF3
5 neutropenia 29.9 IFNA2 IFNA1 CSF3R CSF3
6 leukemia 29.3 U2AF1 TET2 KMT2A JAK2 CSF3R ASXL1
7 myeloproliferative neoplasm 29.1 U2AF1 TET2 LUC7L2 KMT2A JAK2 IFNA2
8 pancytopenia 29.0 U2AF1 LUC7L2 KMT2A CSF3 CD34
9 acute leukemia 28.9 SETBP1 KMT2A JAK2 CSF3R CSF3 CD34
10 neutrophilia, hereditary 28.9 U2AF1 SETBP1 LUC7L2 JAK2 CSF3R CSF3
11 myeloma, multiple 28.8 U2AF1 JAK2 IFNA1 CSF3 CD34 ABL1
12 thrombocytopenia 28.5 U2AF1 JAK2 IFNA2 IFNA1 CSF3 CD34
13 thrombocytosis 28.4 U2AF1 TET2 JAK2 IFNA1 CSF3 CALR
14 myeloid leukemia 28.1 U2AF1 TET2 KMT2A JAK2 CSF3R CSF3
15 leukemia, acute lymphoblastic 28.0 U2AF1 KMT2A JAK2 CSF3R CSF3 CD34
16 atypical chronic myeloid leukemia 27.8 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 JAK2
17 chronic myelomonocytic leukemia 27.5 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
18 polycythemia vera 27.3 U2AF1 TET2 JAK2 IFNA2 IFNA1 CSF3R
19 leukemia, chronic myeloid 27.1 U2AF1 SETBP1 LUC7L2 KMT2A JAK2 IFNA2
20 myelofibrosis 27.0 U2AF1 TET2 SRSF2 SETBP1 JAK2 IFNA2
21 essential thrombocythemia 26.9 U2AF1 TET2 JAK2 IFNA2 IFNA1 CSF3
22 myelodysplastic/myeloproliferative neoplasm 26.7 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
23 leukemia, chronic lymphocytic 26.7 U2AF1 TET2 SRSF2 KMT2A JAK2 IFNA1
24 myelodysplastic syndrome 26.4 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
25 leukemia, acute myeloid 25.9 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 KMT2A
26 neutropenia, severe congenital, 3, autosomal recessive 10.3 CSF3R CSF3
27 engraftment syndrome 10.3 IFNA1 CSF3
28 plasma cell neoplasm 10.3
29 bladder cancer 10.3
30 mechanical ectropion 10.3 IFNA2 CD34
31 corneal intraepithelial neoplasm 10.2 IFNA2 IFNA1
32 lymphomatoid granulomatosis 10.2 IFNA2 IFNA1
33 cryoglobulinemia, familial mixed 10.2 IFNA2 IFNA1
34 secondary corneal edema 10.2 IFNA2 IFNA1
35 retinitis pigmentosa and erythrocytic microcytosis 10.1 JAK2 CSF3
36 monoclonal gammopathy of uncertain significance 10.1
37 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
38 graft-versus-host disease 10.1
39 central nervous system leukemia 10.1
40 chronic graft versus host disease 10.1
41 conjunctival squamous cell carcinoma 10.1 IFNA2 IFNA1
42 mental retardation, autosomal dominant 29 10.1 SETBP1 ABL1
43 myeloid sarcoma 10.1 U2AF1 KMT2A CD34
44 patau syndrome 10.1 U2AF1 SRSF2 ASXL1
45 discoid lupus erythematosus 10.1 IFNA2 IFNA1
46 systemic mastocytosis with associated hematologic neoplasm 10.0 TET2 SRSF2 ASXL1
47 childhood acute myeloid leukemia 10.0 TET2 SETBP1 ASXL1
48 squamous papillomatosis 10.0 IFNA2 IFNA1
49 core binding factor acute myeloid leukemia 10.0 JAK2 CSF3
50 gastroenteritis 10.0 IFNA2 IFNA1 CSF3
51 lymphoproliferative syndrome 10.0
52 hyperuricemia 10.0
53 chromosomal triplication 10.0
54 stomatitis 10.0 IFNA2 IFNA1 CSF3
55 b-lymphoblastic leukemia/lymphoma with iamp21 9.9 KMT2A ABL1
56 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 9.9 JAK2 ABL1
57 leukemia, acute lymphoblastic 3 9.9 KMT2A CD34 ABL1
58 precursor t-cell acute lymphoblastic leukemia 9.9 KMT2A CD34 ABL1
59 mast cell neoplasm 9.8 U2AF1 SRSF2 CD34 ASXL1
60 mastocytosis, cutaneous 9.8 TET2 IFNA2 CD34
61 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 9.8 JAK2 ABL1
62 lymphoblastic leukemia, acute, with lymphomatous features 9.8 JAK2 ABL1
63 hairy cell leukemia 9.8 U2AF1 IFNA2 IFNA1
64 amegakaryocytic thrombocytopenia, congenital 9.8 LUC7L2 JAK2 CD34
65 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.8
66 hemophilia a 9.8
67 mycobacterium tuberculosis 1 9.8
68 peripheral vascular disease 9.8
69 non-alcoholic steatohepatitis 9.8
70 pre-eclampsia 9.8
71 hemopericardium 9.8
72 splenic sequestration 9.8
73 nephrotic syndrome 9.8
74 bronchopneumonia 9.8
75 focal segmental glomerulosclerosis 9.8
76 severe pre-eclampsia 9.8
77 gout 9.8
78 toxic shock syndrome 9.8
79 alcohol use disorder 9.8
80 vascular disease 9.8
81 bilirubin metabolic disorder 9.8
82 mucormycosis 9.8
83 amyloidosis 9.8
84 miliary tuberculosis 9.8
85 hemophilia 9.8
86 acquired hemophilia 9.8
87 acquired hemophilia a 9.8
88 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
89 cytokine deficiency 9.8
90 myelodysplastic syndrome with excess blasts 9.8
91 partial deletion of the long arm of chromosome 20 9.8
92 acquired polycythemia 9.8 JAK2 ABL1
93 acquired von willebrand syndrome 9.8 U2AF1 JAK2
94 megakaryocytic leukemia 9.8 U2AF1 KMT2A JAK2
95 refractory cytopenia with multilineage dysplasia 9.8 U2AF1 TET2 SETBP1 ASXL1
96 extracutaneous mastocytoma 9.7 U2AF1 TET2 SRSF2 ASXL1
97 indolent systemic mastocytosis 9.7 U2AF1 TET2 SRSF2 ASXL1
98 combined t cell and b cell immunodeficiency 9.7 JAK2 IFNA1 CSF3 CD34
99 portal vein thrombosis 9.7 JAK2 IFNA2 IFNA1 CALR
100 hepatic vascular disease 9.7 U2AF1 JAK2 CSF3 CD34
101 t-cell acute lymphoblastic leukemia 9.6 U2AF1 KMT2A CD34 ABL1
102 childhood leukemia 9.6 TET2 KMT2A CSF3 ABL1
103 shwachman-diamond syndrome 1 9.5 U2AF1 LUC7L2 CSF3R CSF3 CD34
104 mental retardation, autosomal dominant 33 9.5 JAK2 ABL1
105 acquired immunodeficiency syndrome 9.5 IFNA2 IFNA1 CD34
106 lymphoma, non-hodgkin, familial 9.4 U2AF1 KMT2A JAK2 CSF3 CD34
107 leukocyte disease 9.4 U2AF1 JAK2 IFNA1 CSF3 CD34
108 hypereosinophilic syndrome 9.4 JAK2 IFNA2 IFNA1 ABL1
109 diamond-blackfan anemia 9.4 U2AF1 LUC7L2 JAK2 CD34
110 mixed phenotype acute leukemia 9.4 U2AF1 SETBP1 LUC7L2 KMT2A ABL1
111 sm-ahnmd 9.3 U2AF1 TET2 SRSF2 JAK2 ASXL1
112 acute promyelocytic leukemia 9.3 U2AF1 KMT2A IFNA1 CSF3R CSF3 CD34
113 aggressive systemic mastocytosis 9.2 U2AF1 TET2 SRSF2 IFNA2 IFNA1 ASXL1
114 mastocytosis 9.1 TET2 SRSF2 JAK2 IFNA2 IFNA1 ASXL1
115 blood coagulation disease 9.1 U2AF1 LUC7L2 JAK2 IFNA1 CSF3 CD34
116 blood platelet disease 9.1 U2AF1 LUC7L2 JAK2 IFNA1 CSF3 CD34
117 aplastic anemia 9.0 U2AF1 TET2 IFNA1 CSF3R CSF3 CD34
118 juvenile myelomonocytic leukemia 8.9 U2AF1 TET2 SETBP1 LUC7L2 KMT2A JAK2
119 myelophthisic anemia 8.8 U2AF1 SRSF2 JAK2 CD34 CALR ASXL1
120 chronic eosinophilic leukemia 8.8 U2AF1 TET2 JAK2 IFNA1 ASXL1 ABL1
121 systemic mastocytosis 8.8 U2AF1 TET2 SRSF2 JAK2 IFNA2 IFNA1
122 hematologic cancer 8.5 U2AF1 LUC7L2 KMT2A JAK2 CSF3R CSF3
123 chronic leukemia 7.9 U2AF1 TET2 SRSF2 SETBP1 LUC7L2 JAK2
124 bone marrow cancer 7.9 U2AF1 TET2 SRSF2 LUC7L2 JAK2 CSF3

Graphical network of the top 20 diseases related to Chronic Neutrophilic Leukemia:



Diseases related to Chronic Neutrophilic Leukemia

Symptoms & Phenotypes for Chronic Neutrophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

26 (showing 42, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.08 IFNA1 IFNA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.08 CSF3R
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.08 CSF3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.08 KMT2A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.08 CSF3R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.08 IFNA2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.08 KMT2A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.08 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.08 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.08 IFNA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.08 IFNA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.08 CSF3R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.08 CSF3 CSF3R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.08 ABL1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.08 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.08 LUC7L2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.08 CSF3R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-167 10.08 IFNA2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.08 IFNA1 CSF3R IFNA2 KMT2A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-175 10.08 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.08 IFNA2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.08 LUC7L2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.08 CSF3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-209 10.08 IFNA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.08 CSF3R
26 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.08 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.08 IFNA2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.08 IFNA2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.08 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.08 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.08 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.08 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.08 IFNA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.08 IFNA2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.08 KMT2A
36 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.08 IFNA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.08 IFNA1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.08 IFNA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.08 CSF3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.08 ABL1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.08 KMT2A
42 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.08 KMT2A

Drugs & Therapeutics for Chronic Neutrophilic Leukemia

Drugs for Chronic Neutrophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 153, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
3
Acyclovir Approved Phase 3 59277-89-3 2022
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
6
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
7
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
8
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
9
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
10
Polyestradiol phosphate Approved Phase 3 28014-46-2
11
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13 Anesthetics, Dissociative Phase 3
14 Neurotransmitter Agents Phase 3
15 Liver Extracts Phase 3
16 Cola Phase 3
17 Analgesics, Opioid Phase 3
18 Antiprotozoal Agents Phase 3
19 Antiparasitic Agents Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Narcotics Phase 3
22 Analgesics Phase 3
23 valacyclovir Phase 3
24 Anesthetics Phase 3
25 Anesthetics, General Phase 3
26 Anesthetics, Intravenous Phase 3
27 Amebicides Phase 3
28 Liposomal amphotericin B Phase 3
29 Estradiol 17 beta-cypionate Phase 3
30 Contraceptives, Oral Phase 3
31 Contraceptive Agents Phase 3
32 Contraceptives, Oral, Combined Phase 3
33 Estradiol 3-benzoate Phase 3
34 Norgestimate, ethinyl estradiol drug combination Phase 3
35
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
36
alemtuzumab Approved, Investigational Phase 2 216503-57-0
37
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
38
Caspofungin Approved Phase 2 162808-62-0, 179463-17-3 2826718 468682
39
Promethazine Approved, Investigational Phase 2 60-87-7 4927
40
Acetaminophen Approved Phase 2 103-90-2 1983
41
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
42
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
43
Benzyl alcohol Approved Phase 2 100-51-6 244
44
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
45
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
46
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
47
Melphalan Approved Phase 2 148-82-3 460612 4053
48
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
51
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
52
Etoposide Approved Phase 2 33419-42-0 36462
53
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
54
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
55
rituximab Approved Phase 2 174722-31-7 10201696
56
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
57
Carmustine Approved, Investigational Phase 2 154-93-8 2578
58
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
59
Mesna Approved, Investigational Phase 2 3375-50-6 598
60 Molgramostim Investigational Phase 1, Phase 2 99283-10-0
61 Pevonedistat Investigational Phase 1, Phase 2 905579-51-3
62 Rho(D) Immune Globulin Phase 2
63 Immunoglobulins, Intravenous Phase 2
64 gamma-Globulins Phase 2
65
Beclomethasone Phase 2 4419-39-0 20469
66 Anti-Asthmatic Agents Phase 2
67 Antineoplastic Agents, Hormonal Phase 2
68 Tin Fluorides Phase 2
69 Sodium Channel Blockers Phase 1, Phase 2
70 Adjuvants, Immunologic Phase 1, Phase 2
71 Interleukin-2 Phase 1, Phase 2
72 Interleukin-4 Phase 1, Phase 2
73 Anticonvulsants Phase 1, Phase 2
74 Diuretics, Potassium Sparing Phase 1, Phase 2
75 polysaccharide-K Phase 1, Phase 2
76 Gastrointestinal Agents Phase 2
77 Anti-Bacterial Agents Phase 2
78 Anti-Infective Agents Phase 2
79 Immunoglobulins Phase 2
80 Antibodies Phase 2
81 Thymoglobulin Phase 2
82 Antilymphocyte Serum Phase 2
83 Hormone Antagonists Phase 2
84 glucocorticoids Phase 2
85 Anti-Inflammatory Agents Phase 2
86 Antifungal Agents Phase 2
87 Antiviral Agents Phase 2
88 Etoposide phosphate Phase 2
89 Antineoplastic Agents, Immunological Phase 2
90 Neuroprotective Agents Phase 2
91 Antibodies, Monoclonal Phase 2
92 diuretics Phase 2
93
Cefepime Approved, Investigational Phase 1 88040-23-7 5479537
94
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
95
Sunitinib Approved, Investigational Phase 1 557795-19-4, 341031-54-7 5329102
96
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
97
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
98
Pancrelipase Approved, Investigational Phase 1 53608-75-6
99
Thiotepa Approved, Investigational Phase 1 52-24-4 5453
100
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
101
Fenretinide Investigational Phase 1 65646-68-6
102
tipifarnib Investigational Phase 1 192185-72-1 159324
103
Motexafin gadolinium Investigational Phase 1 246252-06-2, 156436-89-4 12047567
104 Protein Kinase Inhibitors Phase 1
105 Imatinib Mesylate Phase 1 220127-57-1 123596
106 Histone Deacetylase Inhibitors Phase 1
107 Anti-Retroviral Agents Phase 1
108 Angiogenesis Inhibitors Phase 1
109 pancreatin Phase 1
110
Liposomal doxorubicin Phase 1 31703
111 Photosensitizing Agents Phase 1
112 Tissue Plasminogen Activator Phase 1
113
Lithium carbonate Approved 554-13-2
114
Mechlorethamine Approved, Investigational 51-75-2 4033
115
Foscarnet Approved 4428-95-9, 63585-09-1 3415
116
Valganciclovir Approved, Investigational 175865-60-8 64147
117
Ganciclovir Approved, Investigational 82410-32-0 3454
118
Dapsone Approved, Investigational 80-08-0 2955
119
Voriconazole Approved 137234-62-9 71616
120
Itraconazole Approved, Investigational 84625-61-6 55283
121
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
122
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
123
Granisetron Approved, Investigational 109889-09-0 3510
124
Pemetrexed Approved, Investigational Early Phase 1 137281-23-3, 150399-23-8 60843 446556
125
Morphine Approved, Investigational 57-27-2 5288826
126
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
127
Methadone Approved 76-99-3 4095